BASF Unveils 41% Damaged Collagen Reduction Peptide and Recombinant Collagen III
In-cosmetics Global, the spring trade event for cosmetic raw materials, opened in Paris on April 9, 2026, and BASF used the same day to unveil two collagen launches at once. One is a precision peptide that selectively flags damaged collagen, the other a recombinant Collagen III fragment produced through yeast fermentation. Two distinct approaches to collagen, presented at the same event.
A precision peptide that tags only damaged collagen
NeoHelix Regenerate marks the first cosmetic application of collagen-hybridizing peptide (CHP) technology. Originally developed by U.S. startup 3Helix for medical imaging, the peptide binds to unfolded triple-helix strands of damaged collagen, locking onto them like a key in a damaged lock. It selectively recognizes injured collagen without touching the intact structure.
In a 56-day clinical study with 5 women aged 60 to 70, damaged collagen decreased by 41 percent and hyaluronic acid levels increased by 65 percent. BASF reported that NeoHelix Regenerate outperformed a comparator peptide benchmark across all parameters. The sample size of five is a limitation, but it functions as a first-stage mechanistic validation.
Yeast-made human-identical Collagen III
SkinNexus Collag3n takes a different route. Instead of extraction from animal sources, it uses vegan yeast fermentation to produce a fragment with a 100% human-identical Collagen III sequence. The platform was developed in partnership with Bota Biosciences, which operates the AI-driven SAION biomanufacturing platform.
In a 3D dermis model, Collagen I increased by 48 percent, Collagen III by 82 percent, and Collagen V by 71 percent. A clinical study in women aged 53 to 70 showed measurable improvements in skin tonicity, sagging, and fine wrinkles after 4 weeks. BASF emphasized that the active matched a benchmark collagen ingredient at one-tenth the concentration.
Why Collagen III is gaining attention
Roughly 80 percent of skin collagen is Collagen I, but Collagen III provides the structural framework of the dermis as a “reinforcing matrix.” Younger skin has a higher III to I ratio, and Collagen III declines first with age, contributing to reduced repair capacity. The arrival of a topical that supplies Collagen III directly suggests that the anti-aging marketing language, which has revolved around Collagen I, may expand toward Collagen III.
A different trajectory from supplements
Worth noting: oral collagen supplements remain anchored to hydrolyzed peptides (1,000 to 5,000 Da). They face different problems of absorption and tissue delivery. Topical collagen has historically been limited by poor dermal penetration and treated as a moisturizing aid. With precision peptides and recombinant fragments now entering the conversation, the efficacy claims for topical collagen are being redefined.
What consumers can expect
These ingredients will not appear on shelves immediately. As a raw material company, BASF licenses to global luxury and dermocosmetic brands first, with finished products typically launching 6 to 18 months later. That said, the language of “recombinant collagen,” “Collagen III,” and “yeast-derived” has already begun appearing in select K-beauty brands, with prices running 2 to 5 times higher than standard collagen topicals. A 30ml ampoule sits in the 80,000 to 250,000 KRW range.
What comes next
BASF’s simultaneous launch reads as a signal of paradigm shift, from collagen as something to “supplement” toward collagen as something to “tag” or “reproduce.” Recognizing only damage to direct repair, or supplying a human-identical sequence directly, both bypass the chronic limitation of hydrolyzed peptides being broken down without clear destination. The statistical power of a five-subject trial will be revisited in future expanded studies, but the mechanistic data marks a meaningful starting point.